J Drugs Dermatol. 2021 Aug 1;20(8):868-873. doi: 10.36849/JDD.5836.
The Symposium on Hidradenitis Suppurativa Advances (SHSA) is a joint meeting of the United States Hidradenitis Suppurativa Foundation (HSF) and the Canadian Hidradenitis Suppurativa Foundation (CHSF). This annual cross-disciplinary meeting brings together experts from around the world in an opportunity to discuss the most recent advances in the study of hidradenitis suppurativa (HS). The fifth annual meeting was held virtually on 9-11 October 2020. A record 347 attendees, including 79 people with HS, from 20 different countries attended. Key take-home points included: Clinicians can optimize each visit by listening, provide education, and discuss treatments; a patient decision aid for HS (HS-PDA) is a freely available tool (www.informed-decisions.org); COVID-19 severity in HS patients was not different for patients treated with/without a biologic; comorbidity screening recommendations will be published soon; neutrophil extracellular traps (NETs) may play a role in HS; memory B cells, T helper 1 cytokines, and interleukin 1 signaling contributes to HS pathogenesis and are targets for new therapies; novel therapies are showing promise including a new JAK1 inhibitor (INCB054707) and brodalumab; and HS-specific outcome measures have emerged to better monitor disease severity, flare, and progression including a patient reported measure (HiSQOL) and an HS-specific investigator global assessment. J Drugs Dermatol. 2021;20(8):868-873. doi:10.36849/JDD.5836.
化脓性汗腺炎进展研讨会 (SHSA) 是美国化脓性汗腺炎基金会 (HSF) 和加拿大化脓性汗腺炎基金会 (CHSF) 的联合会议。该年度跨学科会议汇集了来自世界各地的专家，共同讨论化脓性汗腺炎 (HS) 研究的最新进展。第五届年度会议于 2020 年 10 月 9 日至 11 日在线上举行。来自 20 个不同国家的 347 名与会者（包括 79 名 HS 患者）创纪录地参加了会议。主要收获包括：临床医生可以通过倾听、提供教育和讨论治疗方法来优化每次就诊；一种用于 HS 的患者决策辅助工具 (HS-PDA) 是一种免费工具 (www.informed-decisions.org)；接受/未接受生物制剂治疗的 HS 患者的 COVID-19 严重程度无差异；即将发布共病筛查建议；中性粒细胞胞外陷阱 (NETs) 可能在 HS 中起作用；记忆 B 细胞、辅助性 T 细胞 1 细胞因子和白细胞介素 1 信号传导有助于 HS 的发病机制，是新疗法的靶点；新的疗法显示出希望，包括一种新的 JAK1 抑制剂 (INCB054707) 和 brodalumab；已经出现了针对 HS 的特定结局测量方法，以更好地监测疾病的严重程度、发作和进展，包括患者报告的措施 (HiSQOL) 和 HS 特定的研究者全球评估。皮肤病药物杂志。2021;20(8):868-873. doi:10.36849/JDD.5836.
